The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine.
Paola Queirolo
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Francesco Spagnolo
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Virginia Picasso
No relevant relationships to disclose
Elena Tornari
No relevant relationships to disclose
Vincenzo Ottaviano
No relevant relationships to disclose
Laura Giorello
No relevant relationships to disclose
Ester Simeone
No relevant relationships to disclose
Antonio Maria Grimaldi
No relevant relationships to disclose
Marcello Curvietto
No relevant relationships to disclose
Domenico Franco Merlo
No relevant relationships to disclose
Paolo Antonio Ascierto
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche/Genentech; Ventana
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Research Funding - Bristol-Myers Squibb; Roche/Genentech; Ventana
Paolo Bruzzi
No relevant relationships to disclose